Rigel Pharma (RIGL) Hit as OSKIRA-4 Misses Secondary Endpoint (AZN)
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Join SI Premium – FREE
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) getting hit early following an update on OSKIRA-4 by AstraZeneca (NYSE: AZN). OSKIRA-4 is a Phase IIb monotherapy study of fostamatinib.
Astra said fostamatinib met the primary endpoint, but missed the secondary one "as all fostamatinib monotherapy doses were inferior to adalimumab monotherapy at week 24 based on DAS28."
Shares of Rigel are down 11 percent in early trading Thursday.
Astra said fostamatinib met the primary endpoint, but missed the secondary one "as all fostamatinib monotherapy doses were inferior to adalimumab monotherapy at week 24 based on DAS28."
Shares of Rigel are down 11 percent in early trading Thursday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- NVIDIA (NVDA) in talks to invest in data-center company Cloverleaf Infrastructure - WSJ
- S&P 500 may pull back before midterms, but Citi says buy the dip
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
